Clin Osteol 2026; 31(1): 7-11 | DOI: 10.36290/clo.2026.001

Primary bone tumours: An Orthopaedic PerspectiveMain theme

Jiří Gallo1, Tomáš Tomáš2
1 Ortopedická klinika LF UP a FN Olomouc
2 Ortopedická klinika LF MU a FN u svaté Anny, Brno

Primary bone tumors represent a heterogeneous and relatively rare group of lesions whose biological behavior ranges from benign incidental findings to highly malignant sarcomas. The WHO classification (2020) categorizes tumors according to histogenesis (osteogenic, chondrogenic, etc.); however, for clinical practice, the key distinction is between benign, intermediate (locally aggressive and, in rare cases, metastasizing), and malignant lesions. A crucial clinical task is early triage: to distinguish lesions suitable for observation or elective treatment from suspected malignancies requiring urgent further evaluation and management in a specialized center. Diagnosis is based on an algorithmic approach (X-ray followed by MRI/CT depending on the lesion type; staging in suspected malignancies); in many tumors, definitive classification is only possible after histopathological and molecular examination of a biopsy sample. A key principle is that biopsy should be performed exclusively at the center that will provide subsequent treatment, because an improperly performed biopsy can significantly complicate curative resection. Treatment follows recommended protocols and differs according to biological behavior: benign and intermediate lesions often require observation or targeted intervention, whereas malignant tumors generally involve a combination of surgery, systemic therapy, and/or radiotherapy within a multidisciplinary team.

Keywords: primary bone tumors, benign, intermediate, bone sarcomas, diagnostic algorithm, biopsy, specialized center care.

Accepted: March 24, 2026; Published: March 30, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gallo J, Tomáš T. Primary bone tumours: An Orthopaedic Perspective. Clinical Osteology. 2026;31(1):7-11. doi: 10.36290/clo.2026.001.
Download citation

References

  1. Hosseini H, Heydari S, Hushmandi K, et al. Bone tumors: a systematic review of prevalence, risk determinants, and survival patterns. BMC Cancer. 2025;25(1):321. Go to original source... Go to PubMed...
  2. Dungl P, et al. Ortopedie. 2nd ed. Praha: Grada Publishing; 2014.
  3. Biermann JS, Hirbe A, Ahlawat S, et al. Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(4):???. Go to original source... Go to PubMed...
  4. Nielsen GP, Rosenberg AE, Bovée JVMG, et al. Tumors of the Bones and Joints. Arlington, VA: American Registry of Pathology; 2021. Go to original source...
  5. Green NM, Abas S, Sajid S, et al. Presentation of bone tumours: clinical findings and initial management of patients. Orthop Trauma. 2021;35(3):108-114. Go to original source...
  6. Broski SM, Littrell LA, Howe BM, et al. Bone Tumors: Common Mimickers. Radiol Clin North Am. 2022;60(2):239-252. Go to original source... Go to PubMed...
  7. Carter JM, Howe BM, Inwards CY. Conditions Simulating Primary Bone Neoplasms. Surg Pathol Clin. 2017;10(3):731-748. Go to original source... Go to PubMed...
  8. Strauss SJ, Frezza AM, Abecassis N, et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(12):1520-1536. Go to original source... Go to PubMed...
  9. Tsuchiya K, Akisue T, Ehara S, et al. Japanese orthopaedic association (JOA) clinical practice guideline on the management of primary malignant bone tumors - Secondary publication. J Orthop Sci. 2025;30(1):1-17. Go to original source... Go to PubMed...
  10. Hinterwimmer F, Serena RS, Wilhelm N, et al. Recommender-based bone tumour classification with radiographs-a link to the past. Eur Radiol. 2024;34(10):6629-6638. Go to original source... Go to PubMed...
  11. Altsitzioglou P, Tsukamoto S, Errani C, et al. Predicting the Risk for Pathological Fracture in Bone Metastases. Curr Oncol. 2025;32(6):???. Go to original source... Go to PubMed...
  12. Bryson DJ, Wicks L, Ashford RU. The investigation and management of suspected malignant pathological fractures: a review for the general orthopaedic surgeon. Injury. 2015;46(10):1891-1899. Go to original source... Go to PubMed...
  13. Mahdal M, Pazourek L, Apostolopoulos V, et al. Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis. Curr Oncol. 2022;29(5):3519-3530. Go to original source... Go to PubMed...
  14. Morris R, Shepherd K, Cribb G, et al. Bone biopsy results in patients with a history of malignancy: a case series of 378 patients. Skeletal Radiol. 2021;50(6):1111-1116. Go to original source... Go to PubMed...
  15. Chambers M, O'Hern K, Kerr DA. Fine-needle aspiration biopsy for the diagnosis of bone and soft tissue lesions: a systematic review and meta-analysis. J Am Soc Cytopathol. 2020;9(5):429-441. Go to original source... Go to PubMed...
  16. Mavrogenis AF, Angelini A, Vottis C, et al. State-of-the-art approach for bone sarcomas. Eur J Orthop Surg Traumatol. 2015;25(1):5-15. Go to original source... Go to PubMed...
  17. Hill D, Williamson T, Lai CY, et al. Automated resection planning for bone tumor surgery. Comput Biol Med. 2021;137:104777. Go to original source... Go to PubMed...
  18. Lesensky J, Mavrogenis AF. Cement Intercalary Reconstruction After Bone Tumor Resection. Orthopedics. 2021;44(4):e593-e599. Go to original source... Go to PubMed...
  19. Lesensky J, Prince DE. Distraction osteogenesis reconstruction of large segmental bone defects after primary tumor resection: pitfalls and benefits. Eur J Orthop Surg Traumatol. 2017;27(6):715-727. Go to original source... Go to PubMed...
  20. Apostolopoulos V, Mahdal M, Pazourek L, et al. Soft tissue reconstruction using Trevira tube following proximal femur resection and tumorous endoprosthetic replacement. BMC Musculoskelet Disord. 2025;26(1):703. Go to original source... Go to PubMed...




Clinical Osteology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.